Skip to content
Go back

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA

Clinical Nutrition – 2017

Authors

Ingvild Paur, Wolfgang Lilleby, Siv Kjølsrud Bøhn, Erik Hulander, Willibrord Klein, Ljiljana Vlatkovic, Karol Axcrona, Nils Bolstad, Trine Bjøro, Petter Laake, Kristin A.Taskén, Aud Svindland, Lars Magne Eri, Bjørn Brennhovd, Monica H. Carlsen, Sophie D. Fosså, Sigbjørn S. Smeland, Anette S. Karlsen, Rune Blomhoff

Journal

Clinical Nutrition

Year

2017

Background & aims

The effect of lycopene-containing foods in prostate cancer development remains undetermined. We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients.

Methods

Prior to their curative treatment, 79 patients with prostate cancer were randomized to a nutritional intervention with either 1) tomato products containing 30 mg lycopene per day; 2) tomato products plus selenium, omega-3 fatty acids, soy isoflavones, grape/pomegranate juice, and green/black tea (tomato-plus); or 3) control diet for 3 weeks.

Results

The main analysis, which included patients in all risk categories, did not reveal differences in changes of PSA-values between the intervention and control groups. Post-hoc, exploratory analyses within intermediate risk (n = 41) patients based on tumor classification and Gleason score post-surgery, revealed that median PSA decreased significantly in the tomato group as compared to controls (−2.9% and +6.5% respectively, p = 0.016). In separate post-hoc analyses, we observed that median PSA-values decreased by 1% in patients with the highest increases in plasma lycopene, selenium and C20:5 n-3 fatty acid, compared to an 8.5% increase in the patients with the lowest increase in lycopene, selenium and C20:5 n-3 fatty acid (p = 0.003). Also, PSA decreased in patients with the highest increase in lycopene alone (p = 0.009).

Conclusions

Three week nutritional interventions with tomato-products alone or in combination with selenium and n-3 fatty acids lower PSA in patients with non-metastatic prostate cancer. Our observation suggests that the effect may depend on both aggressiveness of the disease and the blood levels of lycopene, selenium and omega-3 fatty acids.